Recommendations for the management of hepatitis C virus infection among people who inject drugs

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Robaeys, Geert ^a,b,c   Grebely, Jason ^d   Mauss, Stefan ^e   Bruggmann, Philip ^f   Moussalli, Joseph ^g,h   De Gottardi, Andrea ⁱ   Swan, Tracy ^j   Arain, Amber ^a,c   Kautz, Achim ^k   Stöver, Heino ^l   Wedemeyer, Heiner ^m   Schaefer, Martin ^n,o   Taylor, Lynn ^p   Backmund, Markus ^q,r   Dalgard, Olav ^s   Prins, Maria ^t,u   Dore, Gregory J ^d,v  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e Center for HIV and Hepatogastroenterology   (Germany)

^f Arud Centres of Addiction Medicine   (Switzerland)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j Treatment Action Group   (United States)

^k European Liver Patients Association   (United States)

^l FRANKFURT UNIVERSITY OF APPLIED SCIENCES   (Germany)

^m LEIBNIZ UNIVERSITY HANNOVER   (Germany)

ⁿ KLINIKEN ESSEN MITTE   (Germany)

^o CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^p BROWN UNIVERSITY   (United States)

^q UNIVERSITY OF MUNICH   (Germany)

^r Praxiszentrum im Tal   (Germany)

^s AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^t DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^u ACADEMIC MEDICAL CENTER   (Netherlands)

^v ST VINCENT S HOSPITAL   (Australia)

more..

Author keywords

Drug users; Guidelines; HCV; HIV; Injecting; Injection

Indexed keywords

BOCEPREVIR; BUPRENORPHINE; METHADONE; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EVALUATION AND FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICATION COMPLIANCE; MIXED INFECTION; MONOTHERAPY; MORTALITY; PEOPLE WHO INJECT DRUG; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REINFECTION; RISK FACTOR; SOCIAL SUPPORT; TREATMENT DURATION; TREATMENT RESPONSE;

DRUG USERS; GUIDELINES; HCV; HIV; INJECTING; INJECTION;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84880966007     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit302     Document Type: Article

References (130)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
2. Grebely J, Dore GJ. What is killing people with hepatitis C virus infection? Seminars Liver Dis 2011; 31: 331-9.
3. National Institutes of Health. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26(3 suppl 1):2S-10.
4. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49: 561-73.
5. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-7.
6. Lindenburg CE, Lambers FA, Urbanus AT, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011; 23: 23-31.
7. Dore GJ, Hellard M, Matthews GV, et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010; 138:123-35.e1-2.
8. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38: 338-45.
9. Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2010; 22: 1050-7.
10. Martinez AD, Dimova R, Marks KM, et al. Integrated internist- addiction medicine-hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat 2010; 19: 47-54.
11. Van Thiel DH, Molloy PJ, Friedlander L, et al. Interferon alpha treatment of chronic hepatitis C in patients with evidence for co-existent autoimmune dysregulation. Hepatogastroenterology 1995; 42: 900-6.
12. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.
13. Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clin Infect Dis 2005; 40(suppl 5): S336-8.
14. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117-23.
15. Neri S, Bruno CM, Abate G, et al. Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002; 24: 1627-35.
16. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.
17. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol 2003; 98: 2281-8.
18. Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004; 40: 120-4.
19. Matthews G, Kronborg IJ, Dore GJ. Treatment for hepatitis C virus infection among current injection drug users in Australia. Clin Infect Dis 2005; 40(suppl 5):S325-9.
20. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005; 29: 159-65.
21. Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Bruckers L, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. Eur J Gastroenterol Hepatol 2006; 18: 159-66.
22. Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 2007; 45: 111-7.
23. Guadagnino V, Trotta MP, Montesano F, et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction 2007; 102: 423-31.
24. Grebely J, Raffa JD, Meagher C, et al. Directly observed therapy for the treatment of hepatitis C virus infection in current and former injection drug users. J Gastroenterol Hepatol 2007; 22: 1519-25.
25. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-43.
26. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46: 991-8.
27. Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepat 2008; 15: 747-52.
28. Papadopoulos V, Gogou A, Mylopoulou T, Mimidis K. Should active injecting drug users receive treatment for chronic hepatitis C? Arq Gastroenterol 2010; 47: 238-41.
29. Manolakopoulos S, Deutsch MJ, Anagnostou O, et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int 2010; 30: 1454-60.
30. Wilkinson M, Crawford V, Tippet A, et al. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment Pharmacol Ther 2009; 29: 29-37.
31. Jack K, Willott S, Manners J, Varnam MA, Thomson BJ. Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 2009; 29: 38-45.
32. Jafferbhoy H, Miller MH, Dunbar JK, Tait J, McLeod S, Dillon JF. Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection. J Viral Hepat 2012; 19: 112-9.
33. Alvarez-Uria G, Day JN, Nasir AJ, Russell SK, Vilar FJ. Factors associated with treatment failure of patients with psychiatric diseases and injecting drug users in the treatment of genotype 2 or 3 hepatitis C chronic infection. Liver Int 2009; 29: 1051-5.
34. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2012; 56: 806-16.
35. Sasadeusz JJ, Dore G, Kronborg I, Barton D, Yoshihara M, Weltman M. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011; 106: 977-84.
36. Sherman M, Bain V, Villeneuve JP, et al. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol 2004; 18: 715-28.
37. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
38. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
39. Iversen J, Grebely J, Topp L, et al. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011 [published online ahead of print 1 July 2013]. J Viral Hepat 2013; doi:10.1111/jvh.12129.
40. Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33.
41. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-8.
42. Strathdee SA, Latka M, Campbell J, et al. Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clin Infect Dis 2005; 40(suppl 5):S304-12.
43. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology 2005; 42: 711-23.
44. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83.
45. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 1099-109.
46. Pybus OG, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol 2005; 5: 131-9.
47. van Asten L, Verhaest I, Lamzira S, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis 2004; 189: 292-302.
48. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31(suppl 2): 61-80.
49. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011; 106: 1978-88.
50. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and metaanalysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011; 204: 74-83.
51. van den Berg CH, Smit C, Bakker M, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol 2007; 22: 183-93.
52. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J Hepatol 2011; 54: 1137-44.
53. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41.
54. John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol 2010; 53: 245-51.
55. Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994-2000. Drug Alcohol Depend 2005; 79: 137-43.
56. Kreek MJ, Dodes L, Kane S, Knobler J, Martin R. Long-term methadone maintenance therapy: effects on liver function. Ann Intern Med 1972; 77: 598-602.
57. Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9: 265-9.
58. Andreu V, Mas A, Bruguera M, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998; 29: 394-7.
59. Turillazzi E, Riezzo I, Neri M, Bello S, Fineschi V. MDMA toxicity and pathological consequences: a review about experimental data and autopsy findings. Curr Pharm Biotechnol 2010; 11: 500-9.
60. Karch SB, Stephens BG, Ho CH. Methamphetamine-related deaths in San Francisco: demographic, pathologic, and toxicologic profiles. J Forensic Sci 1999; 44: 359-68.
61. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005; 3: 1150-9.
62. Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease accelerators during chronic hepatitis C. J Hepatol 2008; 48: 657-65.
63. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63-71.
64. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008; 6: 69-75.
65. Costentin CE, Roudot-Thoraval F, Zafrani ES, et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 2011; 54: 1123-9.
66. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010; 51: 201-9.
67. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-600.
68. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140:1970-9, 9.e1-3.
69. Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11:91.
70. Liu S, Schwarzinger M, Carrat F, Goldhaber-Fiebert JD. Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. PLoS One 2011; 6:e26783.
71. Moessner BK, Jorgensen TR, Skamling M, et al. Outreach screening of drug users for cirrhosis with transient elastography. Addiction 2011; 106: 970-6.
72. Foucher J, Reiller B, Jullien V, et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. J Viral Hepat 2009; 16: 121-31.
73. Grebely J, Tyndall MW. Management of HCV and HIV infections among people who inject drugs. Curr Opin HIVAIDS 2011; 6: 501-7.
74. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93: 141-7.
75. Treloar C, Hull P, Bryant J, Hopwood M, Grebely J, Lavis Y. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs. Drug Alcohol Depend 2011; 116: 52-6.
76. Treloar C, Newland J, Rance J, Hopwood M. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. J Viral Hepat 2010; 17: 839-44.
77. Doab A, Treloar C, Dore GJ. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clin Infect Dis 2005; 40 (suppl 5):S313-20.
78. Kramer JR, Kanwal F, Richardson P, Giordano TP, Petersen LA, El- Serag HB. Importance of patient, provider, and facility predictors of hepatitis C virus treatment in veterans: a national study. Am J Gastroenterol 2011; 106: 483-91.
79. Gidding HF, Law MG, Amin J, et al. Predictors of deferral of treatment for hepatitis C infection in Australian clinics. Med J Aust 2011; 194: 398-402.
80. Bini EJ, Brau N, Currie S, et al. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-9.
81. Kanwal F, Hoang T, Spiegel BM, et al. Predictors of treatment in patients with chronic hepatitis C infection - role of patient versus nonpatient factors. Hepatology 2007; 46: 1741-9.
82. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (5 suppl 1):S35-46.
83. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
84. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
85. Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
86. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-17.
87. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 257-64.
88. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
89. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
90. Chayama K, Takahashi S, Kawakami Y, et al. Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virological response (SVR12) in HCV genotype 1b-infected null responders. Hepatology 2011; 54(4 suppl):1428A.
91. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
92. Poordad F, Lawitz E, Kowdley KV, et al. 12-week interferon-free regimen of ABT-450/r+ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 2012; 56:S549-50.
93. van Heeswijk R, Vandevoorde A, Verboven P, et al. Pharmacokinetic interaction between telaprevir and methadone. Antimicrob Agents Chemother 2013; 57: 2304-9.
94. Hulskotte EGJ, Feng H, Bruce DR, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Abstract PK 09. In: Seventh International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, 27-28 June 2012.
95. Luo X, Trevejo J, Van Heeswijk RP, Smith F, Garg V. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother 2012; 56: 3641-7.
96. Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D. Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009; 30: 14-27.
97. Grebely J, Matthews GV, Hellard M, et al. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55: 76-85.
98. Marcellin P, Chousterman M, Fontanges T, et al. Adherence to treatment and quality of life during hepatitis C therapy: a prospective, reallife, observational study. Liver Int 2011; 31: 516-24.
99. Smith SR, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother 2007; 41: 1116-23.
100. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19: 741-7.
101. Aspinall E, Corson S, Doyle J, et al. Peginterferon and ribavirin treatment for chronic hepatitis C virus in people who inject drugs: a systematic review and meta-analysis. Clin Infect Dis 2013; 57(Suppl 2):S80-9.
102. Lo Re V 3rd, Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009; 48: 186-93.
103. Sola R, Galeras JA, Montoliu S, et al. Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment. AIDS Res Hum Retroviruses 2006; 22: 393-400.
104. Cournot M, Glibert A, Castel F, et al. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004; 28(6-7 Pt 1): 533-9.
105. Anand BS, Currie S, Dieperink E, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006; 130: 1607-16.
106. Bruggmann P, Dampz M, Gerlach T, Kravecz L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. Drug Alcohol Depend 2010; 110: 167-71.
107. Schaefer M, Sarkar R, Diez-Quevedo C. Management of mental health problems prior to and during treatment of HCV infection in patients with drug addiction. Clin Infect Dis 2013; 57(Suppl 2):S111-7.
108. Alavi M, Grebely J, Matthews GV, et al. Impact of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 957-65.
109. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002; 7: 942-7.
110. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64: 708-14.
111. Evon DM, Ramcharran D, Belle SH, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol 2009; 104: 2949-58.
112. Schmidt F, Janssen G, Martin G, et al. Factors influencing long-term changes in mental health after interferon-alpha treatment of chronic hepatitis C. Aliment Pharmacol Ther 2009; 30: 1049-59.
113. Hauser P, Morasco BJ, Linke A, et al. Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorder. Psychosomatics 2009; 50: 500-5.
114. Bruggmann P, Litwin AH. Models of care for the management of HCV among people who use drugs: one size does not fit all. Clin Infect Dis 2013; 57(Suppl 2):S56-61.
115. Grady B, Schinkel J, Dalgard O. Hepatitis C virus reinfection following treatment among people who use drugs. Clin Infect Dis 2013; 57 (Suppl 2):S105-10.
116. Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011; 8: 265-74.
117. Strader DB. Coinfection with HIV and hepatitis C virus in injection drug users and minority populations. Clin Infect Dis 2005; 41(suppl 1): S7-13.
118. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
119. Taylor LE, Swan T, Matthews GV. Management of HCV/HIV coinfection among people who use drugs in the era of direct-acting antiviral- based therapy. Clin Infect Dis 2013; 57(Suppl 2):S118-24.
120. Rosenberg SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ. Hepatitis C virus and HIV co-infection in people with severe mental illness and substance use disorders. AIDS 2005; 19(suppl 3):S26-33.
121. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
122. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
123. Hwang LY, Grimes CZ, Tran TQ, et al. Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial. J Infect Dis 2010; 202: 1500-9.
124. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009; 136:496-504.e3.
125. Kucirka LM, Farzadegan H, Feld JJ, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010; 202: 845-52.
126. Rizzetto M. Current management of delta hepatitis. Liver Int 2013; 33 (suppl 1): 195-7.
127. De Gottardi A, Hilleret MN, Gelez P, et al. Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome. Clin Transplant 2010; 24: 564-71.
128. Robaeys G, Nevens F, Starkel P, et al. Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection. Transplant Proc 2009; 41: 589-94.
129. Webb K, Shepherd L, Neuberger J. Illicit drug use and liver transplantation: is there a problem and what is the solution? Transpl Int 2008; 21: 923-9.
130. Kanchana TP, Kaul V, Manzarbeitia C, et al. Liver transplantation for patients on methadone maintenance. Liver Transpl 2002; 8: 778-82.